Cardiology

Mandeep Mehra, MD, President of the HFSA, discusses the importance of team-based care between physicians, pharmacists, and nurse practitioners in treating heart failure.

Bertram Pitt, MD, of the University of Michigan School of Medicine, discusses the benefits of subcutaneous furosemide keeping patients from "bouncing back" into the hospital.

Amil Shah, MD, of Harvard Medical School, discusses the utilization of echocardiography - often the first step for the indication of heart failure with preserved ejection fraction - to diagnose patients with the condition and separate them from other morbidities.

James Udelson, MD, the chief of cardiology at Tufts Medical Center, discusses the possibilities offered by the development of subcutaneous furosemide for HF patients in need of diuresis.

One study has shown that 90-day prescriptions can increase adherence over 30-day prescriptions.

Five-year mortality rates decreased 7% for those who were part of the triple-screened group of the study.

No strokes were experienced by the apixaban group, compared to 6 in the warfarin arm of the study.

A 51-year-old man is seen in ED for progressive dyspnea, near syncope on exertion, bilateral edema. What does the tracing tell you?

Rivaroxaban plus aspirin showed a 31% reduction in major cardiovascular events for PAD patients.

A new meta-analysis finds that routine intake of artificial sweeteners is linked to the opposite of the intended effect.

Despite receiving cardiac catheterization at lower rates than other weight categories, underweight patients were more likely to die, be readmitted, and have higher hospital costs.

The novel therapy showed sinus rhythm was present in 75% of patients after 1-year follow-up.

There are currently no known reports of patient harm for the 465,000 implanted devices in question, according to the FDA.

The drug was found to be most effective in its 150 mg and 300 mg doses, reducing cardiovascular events by 15% and 14%, respectively.

Catheter ablation lowered mortality rates to 13.4% and hospitalization rates to 20.7%, significant decreases compared to the conventional methods.

The drug showed a 29% reduction in risk for patients who had a myocardial infarction.

The drug will be reviewed based on the results of the phase 3 HAVEN 1 and 2 studies.

Evolocumab was shown to lower cardiovascular risk between 15 to 20% in a randomized, double-blind, placebo-controlled study.

The hospital topped the list for the second straight year.

The FDA decision regarding Zelboraf’s approval for Erdheim-Chester disease with BRAF V6000 Mutations is expected by December 2017.

Despite the results of a large-scale trial, some experts questioned the use of beta-blockers for patients that suffered from heart failure and simultaneous AFib when in the presence of beta-adverse medications, like amiodarone.

The valve is the first stented surgical aortic valve that is MRI-safe without restrictions and uses single, one-cut release to increase the ease of implantation.

A secondary study revealed that the presence of diabetes mellitus in patients with chronic heart failure leads to a higher risk of early death.

True or false: Between 1999-2004 and 2005-2010, cancer replaced CV/CHD as leading cause of death in T2D.

The 2017 lipid management guidelines have met both accolades and controversy. Take our quick quiz on the updates.

Caution: Approach every patient with SLE as a “bundle of cardiovascular risks” greater than the sum of its parts

The FDA expanded approval of a self-expanding TAVR platform to include patients who are at an intermediate risk for open-heart surgery.

Though safer for relapsing-remmitting multiple sclerosis than new disease-modifying therapies, the treatment nearly doubles the chance of a patient suffering from a stroke.

L-glutamine is the first SCD treatment approved for pediatric patients, and the first adult treatment approved in nearly 20 years.

The drug reduced risk of overall symptomatic hypoglycemia compared to insulin glargine U100.